Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer of thyroid C-cells, for which few treatment options are available. We have recently reported a role for cyclin-dependent kinase 5 (CDK5) in MTC pathogenesis. We have generated a mouse model, in which MTC proliferation is induced upon conditional overexpression of the CDK5 activator, p25, in C-cells, and arrested by interrupting p25 overexpression. Here, we identify genes and proteins that are differentially expressed in proliferating versus arrested benign mouse MTC. We find that downstream target genes of the tumor suppressor, retinoblastoma protein, including genes encoding cell cycle regulators such as CDKs, cyclins and CDK inhibitors, are significantly upregulated in malignant mouse tumors in a CDK5-dependent manner. Reducing CDK5 activity in human MTC cells down-regulated these cell cycle regulators suggesting that CDK5 activity is critical for cell cycle progression and MTC proliferation. Finally, the same set of cell cycle proteins was consistently overexpressed in human sporadic MTC but not in hereditary MTC. Together these findings suggest that aberrant CDK5 activity precedes cell cycle initiation and thus may function as a tumor-promoting factor facilitating cell cycle protein expression in MTC. Targeting aberrant CDK5 or its downstream effectors may be a strategy to halt MTC tumorigenesis.

Highlights

  • Neuroendocrine tumors (NETs) are rare cancers originating from hormone-secreting neuroendocrine (NE) cells

  • A focused examination uncovered a CDK5dependent increase in expression of genes encoding cell cycle regulators, including CDK2, cyclin-D1, p15INK4b, p16INK4a, p18INK4c, p19INK4d and p21CIP/WAF1

  • The same set of cell cycle proteins are down-regulated in human Medullary thyroid carcinoma (MTC) cells lacking cyclin-dependent kinase 5 (CDK5) activity, suggesting aberrant CDK5 activity is necessary and sufficient to drive expression of these markers

Read more

Summary

Introduction

Neuroendocrine tumors (NETs) are rare cancers originating from hormone-secreting neuroendocrine (NE) cells. Hereditary forms of MTC represent about 25% of cases and result from germline mutation in the RET proto-oncogene [6]. These genetic forms of MTC are often associated with other types of NE cancers and they are referred to as Multiple Endocrine Neoplasia of Type 2 (MEN 2). A better understanding of the drivers of MTC progression, especially in the absence of RET or RAS mutations, is needed to develop more effective treatment strategies. Toward this goal, it is paramount to elucidate additional molecular mechanisms underlying MTC and identify new targets for therapy development

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call